StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
54
This year
5
Publishing Date
2024 - 02 - 26
1
2024 - 02 - 01
1
2024 - 01 - 31
1
2024 - 01 - 24
1
2024 - 01 - 09
1
2023 - 10 - 27
1
2023 - 08 - 23
1
2023 - 04 - 04
1
2023 - 02 - 10
1
2022 - 12 - 22
1
2022 - 12 - 01
1
2022 - 09 - 28
1
2022 - 07 - 04
1
2022 - 06 - 30
1
2022 - 06 - 15
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 05 - 18
1
2022 - 05 - 06
1
2022 - 04 - 26
1
2022 - 04 - 14
1
2022 - 04 - 12
1
2022 - 03 - 04
1
2022 - 02 - 24
1
2022 - 02 - 07
1
2022 - 01 - 07
1
2021 - 10 - 20
1
2021 - 10 - 13
1
2021 - 10 - 07
1
2021 - 09 - 29
1
2021 - 09 - 28
1
2021 - 09 - 24
1
2021 - 09 - 09
1
2021 - 09 - 07
1
2021 - 07 - 23
1
2021 - 07 - 09
1
2021 - 07 - 07
1
2021 - 06 - 24
1
2021 - 06 - 23
1
2021 - 06 - 22
1
2021 - 06 - 09
1
2021 - 05 - 20
1
2021 - 05 - 04
1
2021 - 04 - 09
1
2021 - 04 - 08
1
2021 - 04 - 07
1
2021 - 04 - 06
1
2021 - 03 - 31
1
2021 - 03 - 30
1
2021 - 03 - 19
1
2021 - 03 - 18
2
2021 - 03 - 12
1
2021 - 03 - 08
1
Sector
Finance
1
Health technology
54
Manufacturing
5
Process industries
2
Producer manufacturing
1
Tags
Acquisition
9
Active
10
Antiviral
10
Application
24
Approval
31
Authorization
14
Breast
12
Cancer
66
Candidate
16
Children
18
Clinical-trials-phase-ii
9
Clinical-trials-phase-iii
15
Collaboration
21
Comirnaty®
10
Conference
18
Covid
58
Covid-19
41
Disease
28
Drug
54
Earnings
20
Ema
10
Emergency use authorization
10
Europe
13
Events
12
Expected
10
Fda
74
Fda-approvals
14
Financial
19
Global
56
Growth
29
Hiv
15
Hormone
10
License
19
Market
100
Merge
15
N/a
432
Order
15
People
24
Pharm-country
34
Pharmaceutical
17
Phase 2
12
Phase 3
21
Positive
45
Potential
11
Product-news
10
Regulatory
12
Report
49
Research
51
Respiratory
10
Results
62
Risk
16
Study
20
Therapeutics
40
Therapy
29
Topline
14
Treatment
74
Trial
47
Ulcerative colitis
12
Update
14
Vaccine
106
Entities
3m company
10
Abbott laboratories
65
Abbvie inc.
75
Agilent technologies, inc.
10
Aldeyra therapeutics, inc.
10
Aligos therapeutics, inc.
17
Alnylam pharmaceuticals, inc.
11
Amgen inc.
54
Arcutis biotherapeutics, inc.
11
Ardelyx, inc.
11
Arrival
11
Astellas pharma inc
27
Astrazeneca plc
70
Bausch health companies inc.
22
Baxter international inc.
15
Becton, dickinson and company
34
Bio-rad laboratories, inc.
12
Biogen inc.
28
Boston scientific corporation
13
Bristol-myers squibb company
63
Calliditas therapeutics ab
10
Catalent, inc.
10
Certara inc
11
Charles river laboratories international, inc.
13
Danaher corporation
14
Eli lilly and company
105
Endo international plc
13
Enveric biosciences inc
12
Evotec se
20
Galapagos nv
12
Gilead sciences, inc.
25
Glaxosmithkline plc
110
Hoth therapeutics, inc.
12
I-mab
11
Incyte corporation
33
Intelligent bio solutions inc
19
Ionis pharmaceuticals, inc.
14
Jaguar health, inc.
33
Johnson & johnson
224
Laboratory corporation of america holdings
14
Lantern pharma inc.
33
Lexaria bioscience corp
11
Mannkind corporation
12
Medtronic plc
24
Nanoviricides, inc.
21
Novartis ag
116
Novo nordisk a/s
18
Orange
27
Perrigo company
13
Pfizer, inc.
54
Sanofi
241
Sorrento therapeutics, inc.
11
Sutro biopharma, inc.
12
Takeda pharmaceutical company limited
30
Teva pharmaceutical industries ltd
44
Thermo fisher scientific inc
48
Tonix pharmaceuticals holding corp.
12
Viatris inc.
15
West pharmaceutical services, inc.
14
Zai lab limited
11
Symbols
ABT
9
ALPMF
2
ALPMY
2
AMGN
3
ATR
1
AUTL
1
AZN
9
AZNCF
7
BAX
1
BDX
1
BHC
1
BLUE
1
BMY
4
CPRX
1
CYDY
1
EMN
1
ENDP
1
ENZN
1
EXEL
1
GILD
2
GLAXF
12
GMAB
1
GNMSF
1
GSK
20
HALO
1
IONS
1
IRWD
1
JNJ
16
LLY
4
MMM
1
MYOV
4
NVS
12
NVSEF
7
ORGO
1
ORTX
1
PFE
54
QURE
1
ROIV
1
SNY
9
SNYNF
4
SRNE
1
TAK
2
TEVJF
4
TNXP
1
VCEL
1
VTRS
1
Exchanges
Nasdaq
34
Nyse
54
Crawled Date
2024 - 02 - 27
1
2024 - 02 - 01
1
2024 - 01 - 31
1
2024 - 01 - 24
1
2024 - 01 - 09
1
2023 - 10 - 27
1
2023 - 08 - 23
1
2023 - 04 - 04
1
2023 - 02 - 10
1
2022 - 12 - 22
1
2022 - 12 - 01
1
2022 - 09 - 28
1
2022 - 07 - 04
1
2022 - 06 - 30
1
2022 - 06 - 15
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 05 - 18
1
2022 - 05 - 06
1
2022 - 04 - 26
1
2022 - 04 - 14
1
2022 - 04 - 12
1
2022 - 03 - 04
1
2022 - 02 - 24
1
2022 - 02 - 07
1
2022 - 01 - 07
1
2021 - 10 - 20
1
2021 - 10 - 13
1
2021 - 10 - 07
1
2021 - 09 - 29
1
2021 - 09 - 28
1
2021 - 09 - 24
1
2021 - 09 - 09
1
2021 - 09 - 07
1
2021 - 07 - 23
1
2021 - 07 - 09
1
2021 - 07 - 07
1
2021 - 06 - 24
1
2021 - 06 - 23
1
2021 - 06 - 22
1
2021 - 06 - 09
1
2021 - 05 - 20
1
2021 - 05 - 04
1
2021 - 04 - 09
1
2021 - 04 - 08
1
2021 - 04 - 07
1
2021 - 04 - 06
1
2021 - 03 - 31
1
2021 - 03 - 30
1
2021 - 03 - 19
1
2021 - 03 - 18
2
2021 - 03 - 12
1
2021 - 03 - 08
1
Crawled Time
00:00
1
02:00
1
05:00
1
05:03
1
06:00
2
07:00
2
09:00
1
11:00
7
12:00
6
13:00
4
13:14
1
13:20
1
13:55
1
14:00
1
14:15
1
15:00
4
15:21
1
15:28
1
16:00
1
17:00
4
18:00
1
19:00
2
20:00
2
21:58
1
22:00
5
23:00
1
Source
www.biospace.com
11
www.fda.gov
6
www.globenewswire.com
6
www.prnewswire.com
31
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Drug
entities :
Pfizer, inc.
save search
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published:
2024-02-26
(Crawled : 00:00)
- biospace.com/
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-5.4%
|
O:
-0.32%
H:
0.0%
C:
-1.77%
TNXP
|
$0.1579
-1.31%
-1.33%
1.4M
|
Health Technology
|
-50.31%
|
O:
4.32%
H:
7.17%
C:
2.5%
drug
fibromyalgia
study
Global Sustained Release Coatings Markets, 2018-2022 and 2023-2028: Growing Demand for Controlled Drug Delivery Boosts Expansion
Published:
2024-02-01
(Crawled : 17:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
-1.2%
|
O:
-1.29%
H:
0.0%
C:
-1.38%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-3.03%
|
O:
0.07%
H:
0.83%
C:
0.7%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
-8.41%
|
O:
1.55%
H:
0.79%
C:
0.25%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
2.92%
|
O:
1.27%
H:
1.87%
C:
1.73%
EMN
|
$97.06
0.66%
0.0%
630K
|
Process Industries
|
16.17%
|
O:
0.79%
H:
0.8%
C:
0.77%
drug
expansion
global
growing
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published:
2024-01-31
(Crawled : 02:00)
- prnewswire.com
ALPMF
|
News
|
$9.75
43.47%
200
|
Health Technology
|
-15.58%
|
O:
4.34%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.5
-1.11%
1M
|
Manufacturing
|
-17.63%
|
O:
0.0%
H:
1.38%
C:
0.26%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-2.81%
|
O:
0.56%
H:
1.25%
C:
-0.33%
keytruda
drug
japan
bladder
cancer
treatment
application
advanced
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published:
2024-01-24
(Crawled : 17:00)
- prnewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-7.63%
|
O:
0.39%
H:
0.82%
C:
-0.74%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
-12.03%
|
O:
0.22%
H:
0.43%
C:
-0.39%
SRNE
|
$0.02
-8.85%
200K
|
Health Technology
|
-66.67%
|
O:
-63.33%
H:
263.64%
C:
127.27%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-15.76%
|
O:
0.1%
H:
0.43%
C:
-0.04%
AUTL
|
$4.58
1.33%
1.31%
1.2M
|
Health Technology
|
-17.39%
|
O:
-0.91%
H:
11.52%
C:
4.94%
drug
report
t-cell
global
therapy
market
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published:
2024-01-09
(Crawled : 12:00)
- globenewswire.com
GNMSF
|
News
|
$284.55
3.83%
240
|
Health Technology
|
-13.36%
|
O:
-3.69%
H:
1.71%
C:
-2.41%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-11.22%
|
O:
0.07%
H:
0.88%
C:
-0.68%
GMAB
|
News
|
$28.97
0.94%
0.93%
450K
|
Health Technology
|
-11.6%
|
O:
-1.1%
H:
0.46%
C:
-0.06%
tivdak
drug
license
review
food
cancer
application
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published:
2023-10-27
(Crawled : 06:00)
- prnewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-15.73%
|
O:
-0.32%
H:
0.23%
C:
-3.06%
nefecon
nephropathy
drug
approval
treatment
application
Global Nasal Drug Delivery Technology Market Projected to Reach $111.9 Billion by 2030
Published:
2023-08-23
(Crawled : 22:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
18.89%
|
O:
1.41%
H:
1.07%
C:
-1.39%
AZNCF
|
News
|
$136.2
-4.19%
1.7K
|
Health Technology
|
-0.44%
|
O:
-3.15%
H:
0.77%
C:
0.77%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-28.37%
|
O:
-0.5%
H:
0.45%
C:
-0.86%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-10.08%
|
O:
-1.1%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
16.14%
|
O:
-0.31%
H:
0.6%
C:
-1.06%
ATR
|
$140.32
0.7%
0.0%
300K
|
Process Industries
|
13.72%
|
O:
0.08%
H:
1.6%
C:
1.31%
MMM
|
$92.62
0.38%
0.15%
3M
|
Producer Manufacturing
|
-7.05%
|
O:
-0.38%
H:
1.41%
C:
-0.78%
AZN
|
News
|
$70.12
2.29%
2.24%
4.8M
|
Health Technology
|
1.49%
|
O:
-0.39%
H:
0.46%
C:
-1.37%
drug
reach
global
technology
market
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
Published:
2023-04-04
(Crawled : 11:00)
- biospace.com/
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-36.49%
|
O:
0.22%
H:
0.22%
C:
-1.3%
fda
drug
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Published:
2023-02-10
(Crawled : 23:00)
- biospace.com/
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-39.41%
|
O:
0.37%
H:
1.1%
C:
0.87%
cibinqo
fda
drug
application
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis Everest Medicines announced that its licensing partner, Pfizer Inc. has received acceptance from the U.S. Food and Drug Administration for review a New Drug Application for etrasimod for individuals living with moderately-to-severely active ulcerative colitis.
Published:
2022-12-22
(Crawled : 07:00)
- biospace.com/
CYDY
|
$0.1509
0.06%
810K
|
Manufacturing
|
-28.54%
|
O:
-4.34%
H:
0.35%
C:
-5.13%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-49.17%
|
O:
-0.48%
H:
0.56%
C:
0.45%
fda
drug
active
ema
application
review
food
living
ulcerative colitis
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Published:
2022-12-01
(Crawled : 13:20)
- globenewswire.com
ROIV
|
$10.61
1.43%
1.41%
5.3M
|
Manufacturing
|
97.76%
|
O:
7.28%
H:
2.96%
C:
0.87%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-47.62%
|
O:
0.36%
H:
1.68%
C:
1.53%
drug
candidate
Global Opioid Induced Constipation Drugs Market Report to 2030 - by Drug Type, Prescription Type and Region
Published:
2022-09-28
(Crawled : 15:00)
- prnewswire.com
AZNCF
|
News
|
$136.2
-4.19%
1.7K
|
Health Technology
|
30.26%
|
O:
2.35%
H:
0.0%
C:
-0.68%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-40.44%
|
O:
1.32%
H:
0.31%
C:
-0.54%
IRWD
|
$8.06
1.77%
1.74%
2.8M
|
Health Technology
|
-21.52%
|
O:
1.07%
H:
3.08%
C:
2.41%
AZN
|
News
|
$70.12
2.29%
2.24%
4.8M
|
Health Technology
|
31.72%
|
O:
0.04%
H:
3.14%
C:
2.68%
drug
global
opioid
report
market
A $41.8 Billion Global Opportunity for Small Molecule Drug Discovery by 2026 - New Research from StrategyR
Published:
2022-07-04
(Crawled : 11:00)
- prnewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
Email alert
Add to watchlist
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
Email alert
Add to watchlist
AZN
|
News
|
$70.12
2.29%
2.24%
4.8M
|
Health Technology
|
Email alert
Add to watchlist
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
Email alert
Add to watchlist
AZNCF
|
News
|
$136.2
-4.19%
1.7K
|
Health Technology
|
Email alert
Add to watchlist
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
BMY
|
$49.14
0.43%
0.0%
7.9M
|
Health Technology
|
Email alert
Add to watchlist
drug
research
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
Published:
2022-06-30
(Crawled : 11:00)
- biospace.com/
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-48.29%
|
O:
1.79%
H:
2.31%
C:
1.43%
fda
drug
application
submission
Antihypertensive Drugs Market is Estimated to Rise at a CAGR of 3% during the Forecast Period, observes TMR Study
Published:
2022-06-15
(Crawled : 12:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-4.43%
|
O:
0.08%
H:
0.0%
C:
0.0%
TAK
|
News
|
$13.36
0.91%
-0.52%
1.6M
|
Health Technology
|
0.64%
|
O:
-1.02%
H:
1.6%
C:
1.14%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-44.91%
|
O:
0.48%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-6.1%
|
O:
-0.89%
H:
0.0%
C:
0.0%
market
drug
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Published:
2022-06-02
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-50.6%
|
O:
-1.62%
H:
0.0%
C:
0.0%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
155.37%
|
O:
-2.98%
H:
0.0%
C:
0.0%
myfembree
fda
sciences
drug
application
Antifungal Drugs Market Size to be worth $20.5 Billion by 2030: Grand View Research, Inc.
Published:
2022-05-24
(Crawled : 12:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
-28.93%
|
O:
-2.41%
H:
0.0%
C:
-1.7%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
26.6%
|
O:
0.17%
H:
0.0%
C:
0.0%
ENZN
|
$0.0724
136.11%
540
|
Manufacturing
|
-79.08%
|
O:
-4.13%
H:
4.38%
C:
1.01%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-50.05%
|
O:
0.99%
H:
0.0%
C:
0.0%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
5.22%
|
O:
1.17%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-9.52%
|
O:
-0.13%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-15.8%
|
O:
1.04%
H:
1.53%
C:
1.37%
market
drug
Hydrogel-Based Drug Delivery System Market to Surpass US$ 8,187.6 Million by 2030 - Coherent Market Insights
Published:
2022-05-18
(Crawled : 18:00)
- prnewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-48.85%
|
O:
-0.23%
H:
0.39%
C:
-1.6%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-16.59%
|
O:
0.07%
H:
0.0%
C:
0.0%
drug
system
market
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Published:
2022-05-06
(Crawled : 11:00)
- globenewswire.com
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-46.76%
|
O:
-2.36%
H:
0.0%
C:
0.0%
MYOV
|
$26.98
-0.04%
0.0%
0
|
Health Technology
|
179.59%
|
O:
-1.71%
H:
0.0%
C:
0.0%
myfembree
management
drug
application
Global Genitourinary Drugs Market Research Report to 2027 - Increasing Prevalence of Genitourinary Disorders is Driving Growth
Published:
2022-04-26
(Crawled : 14:00)
- prnewswire.com
ALPMF
|
News
|
$9.75
43.47%
200
|
Health Technology
|
-36.73%
|
O:
2.56%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.5
-1.11%
1M
|
Manufacturing
|
-39.95%
|
O:
0.13%
H:
0.06%
C:
-0.69%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-45.08%
|
O:
3.08%
H:
0.0%
C:
0.0%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
5.49%
|
O:
0.47%
H:
0.83%
C:
-1.44%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-18.34%
|
O:
2.0%
H:
0.0%
C:
0.0%
LLY
|
News
|
$731.33
0.69%
0.0%
2.3M
|
Health Technology
|
156.43%
|
O:
0.34%
H:
1.41%
C:
-1.17%
IONS
|
$41.08
0.98%
0.97%
670K
|
Health Technology
|
-3.0%
|
O:
-0.12%
H:
0.07%
C:
-5.13%
research
report
growth
market
drug
← Previous
1
2
3
Next →
Gainers vs Losers
75%
25%
Top 10 Gainers
MTTR
|
News
M
|
$4.78
174.71%
63.6%
72M
|
AGBA
|
$2.565
105.2%
51.27%
200M
|
Finance
MLEC
|
$2.44
74.29%
42.62%
78M
|
n/a
EDBL
|
News
|
$6.28
67.02%
40.13%
16M
|
ATGL
|
$2.91
48.81%
32.8%
180K
|
ZAPP
|
$0.2175
47.16%
32.05%
16M
|
n/a
ONFO
|
$0.6075
38.38%
27.74%
7.3M
|
n/a
VIVK
|
$1.48
38.32%
27.7%
530K
|
Professional, Scientific, and T...
MNTS
|
$0.5
35.69%
26.3%
4.8M
|
SDIG
A
|
$3.635
35.13%
26.0%
1M
|
Your saved searches
Save your searches and get alerts when important news are released.